Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19850476 | 0.85 | GPR119 (0.47) | GPR119 | |
| SCHEMBL1118384 | 0.84 | GPR119 (0.51) | GPR119 | |
| SCHEMBL1577792 | 0.82 | GPR119 (0.57) | GPR119 | |
| SCHEMBL1118211 | 0.82 | GPR119 (0.68) | GPR119 | |
| SCHEMBL1118366 | 0.81 | GPR119 (0.71) | GPR119 | |
| SCHEMBL16705282 | 0.80 | GPR119 (0.42) | GPR119 | |
| SCHEMBL14139637 | 0.78 | FAAH (0.43) | GPR119 | |
| SCHEMBL1577008 | 0.75 | GPR119 (0.55) | GPR119 | |
| SCHEMBL387306 | 0.75 | GPR119 (0.60) | GPR119 | |
| SCHEMBL1557151 | 0.74 | GPR119 (0.53) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3493807-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CymaBay Therapeutics, Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10292983-B2 | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions | CYMABAY THERAPEUTICS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10292983-B2 | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions | CYMABAY THERAPEUTICS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-9925189-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925189-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925189-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180036307-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CYMABAY THERAPEUTICS INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180036307-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CYMABAY THERAPEUTICS INC (US) | 2018-02-08 | — | — | US | disclosed |
| WO-2018026890-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CYMABAY THERAPEUTICS (US) | 2018-02-08 | — | — | WO | disclosed |
| WO-2018026890-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CYMABAY THERAPEUTICS (US) | 2018-02-08 | — | — | WO | disclosed |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. | 2009-10-29 | — | — | US | disclosed |
| EP-2111107-A2 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | Metabolex Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009123992-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009123992-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008083238-A2 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10292983-B2 | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions | GPR119, GIPR, GLP1R | GPR119 1/4885 |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | GPR119, GLP1R, DPP4 | GPR119 1/4885 |
| US-20180036307-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | GPR119, GIPR, GLP1R | GPR119 1/4885 |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | SLC5A2, IAPP, GPR119 | GPR119 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.